Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy

Tseligka, Eirini D., Rova, Aikaterini, Amanatiadou, Elsa P., Calabrese, Gianpiero, Tsibouklis, John, Fatouros, Dimitrios G. and Vizirianakis, Ioannis S. (2016) Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy. Pharmaceutical Research, 33(8), pp. 1945-1958. ISSN (print) 0724-8741

Full text available as:
Text (The final publication is available at Springer via http://dx.doi.org10.1007/s11095-016-1930-4)
Calabrese-G-35015-AAM.pdf - Accepted Version

Download (1MB) | Preview


PURPOSE: Tumor cell heterogeneity and microenvironment represent major hindering factors in the clinical setting toward achieving the desired selectivity and specificity to malignant tissues for molecularly targeted cancer therapeutics. In this study, the cellular and molecular evaluation of several delocalized lipophilic cation (DLC)-functionalized carborane compounds as innovative anticancer agents is presented. METHODS: The anticancer potential assessment of the DLC-carboranes was performed in established normal (MRC-5, Vero), cancer (U-87 MG, HSC-3) and primary glioblastoma cancer stem (EGFRpos, EGFRneg) cultures. Moreover, the molecular mechanism of action underlying their pharmacological response is also analyzed. RESULTS: The pharmacological anticancer profile of DLC-functionalized carboranes is characterized by: a) a marked in vitro selectivity, due to lower concentration range needed (ca. 10 fold) to exert their cell growth-arrest effect on U-87 MG and HSC-3, as compared with that on MRC-5 and Vero; b) a similar selective growth inhibition behavior towards EGFRpos and EGFRneg cultures (>10 fold difference in potency) without, however, the activation of apoptosis in cultures; c) notably, in marked contrast to cancer cells, normal cells are capable of recapitulating their full proliferation potential following exposure to DLC-carboranes; and, d) such pharmacological effects of DLC-carboranes has been unveiled to be elicited at the molecular level through activation of the p53/p21 axis. CONCLUSIONS: Overall, the data presented in this work indicates the potential of the DLC-functionalized carboranes to act as new selective anticancer therapeutics that may be used autonomously or in therapies involving radiation with thermal neutrons. Importantly, such bifunctional capacity may be beneficial in cancer therapy.

Item Type: Article
Additional Information: This work was supported by Aristotle University and COST 1106 Action
Research Area: Biological sciences
Cancer studies
Faculty, School or Research Centre: Faculty of Science, Engineering and Computing (until 2017) > School of Pharmacy and Chemistry
Related URLs:
Depositing User: Katrina Clifford
Date Deposited: 24 May 2016 10:46
Last Modified: 04 Sep 2017 11:41

Actions (Repository Editors)

Item Control Page Item Control Page